Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

52.95 -0.51 (-0.94%)

Streaming Delayed Price Updated: 3:49 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

1 Top ETF I Plan to Load Up on in 2026 ↗

January 02, 2026

This ETF could produce robust total returns in 2026 and beyond.

Via The Motley Fool

Topics ETFs Stocks

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 02, 2026

From Bristol Myers Squibb

Via Business Wire

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Via StockStory

Topics Stocks

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

2 Dividend Stocks to Scoop Up Without Hesitation Right Now ↗

December 31, 2025

These stocks can be great sources of portfolio growth in the years ahead.

Via The Motley Fool

Topics Bankruptcy Initial Public Offering

Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗

December 30, 2025

The stock has been on the rebound for several months, but can it keep the momentum going?

Via The Motley Fool

Topics Intellectual Property

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗

December 30, 2025

Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Via The Motley Fool

Topics Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Via The Motley Fool

Topics Intellectual Property

Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

December 24, 2025

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition ↗

December 24, 2025

Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.

Via Chartmill

Topics Intellectual Property

Dividend Stocks Are the Gift that Will Keep On Giving You More Income in 2026 ↗

December 24, 2025

These dividend investments can provide you with a growing income stream in 2026.

Via The Motley Fool

Topics Economy

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Via Stocktwits

Topics Government

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Via MarketMinute

Topics Economy

Should Retirees Pull Their Money Out of the Stock Market in 2026? ↗

December 21, 2025

Even if you think the market will slump, selling your holdings isn't an ideal strategy.

Via The Motley Fool

Topics ETFs Economy Retirement

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High-Quality Dividend Profile for Income Investors ↗

December 20, 2025

Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors.

Via Chartmill

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

From Bristol Myers Squibb

Via Business Wire

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

From Bristol Myers Squibb

Via Business Wire

These 2 Healthcare Stocks Just Declared Dividend Raises ↗

December 17, 2025

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Via The Motley Fool

Topics Intellectual Property

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

December 15, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its...

Via StockStory

Stay informed with the top movers within the S&P500 index on Monday. ↗

December 15, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions

December 15, 2025

Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative...

Via PredictStreet

Topics Intellectual Property Lawsuit Supply Chain

Top S&P500 movers in Monday's pre-market session ↗

December 15, 2025

The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.